[go: up one dir, main page]

ZA200103925B - Use of staurosporine derivatives for treating ocular neovascular diseases. - Google Patents

Use of staurosporine derivatives for treating ocular neovascular diseases. Download PDF

Info

Publication number
ZA200103925B
ZA200103925B ZA200103925A ZA200103925A ZA200103925B ZA 200103925 B ZA200103925 B ZA 200103925B ZA 200103925 A ZA200103925 A ZA 200103925A ZA 200103925 A ZA200103925 A ZA 200103925A ZA 200103925 B ZA200103925 B ZA 200103925B
Authority
ZA
South Africa
Prior art keywords
staurosporine
radical
acyclic
treatment
prevention
Prior art date
Application number
ZA200103925A
Other languages
English (en)
Inventor
Brazzell Romulus Kimbro
Wood Jeanette Marjorie
Campochiaro Peter Anthony
Kane Frances Elizabeth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200103925B publication Critical patent/ZA200103925B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200103925A 1998-11-23 2001-05-15 Use of staurosporine derivatives for treating ocular neovascular diseases. ZA200103925B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19867798A 1998-11-23 1998-11-23

Publications (1)

Publication Number Publication Date
ZA200103925B true ZA200103925B (en) 2002-07-25

Family

ID=22734344

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200103925A ZA200103925B (en) 1998-11-23 2001-05-15 Use of staurosporine derivatives for treating ocular neovascular diseases.

Country Status (19)

Country Link
EP (1) EP1131073B1 (zh)
JP (2) JP2002530342A (zh)
KR (1) KR100698449B1 (zh)
CN (1) CN1172673C (zh)
AT (1) ATE252387T1 (zh)
AU (1) AU761092B2 (zh)
BR (1) BR9915569A (zh)
CA (1) CA2348890C (zh)
DE (1) DE69912304T2 (zh)
DK (1) DK1131073T3 (zh)
ES (1) ES2211197T3 (zh)
HK (1) HK1040182A1 (zh)
ID (1) ID29970A (zh)
IL (2) IL142757A0 (zh)
NO (1) NO328085B1 (zh)
NZ (1) NZ511559A (zh)
PT (1) PT1131073E (zh)
WO (1) WO2000030651A1 (zh)
ZA (1) ZA200103925B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
WO2004009056A1 (en) * 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN101580515B (zh) * 2008-05-16 2011-06-08 上海医药工业研究院 一种星形孢菌素提取纯化的方法
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102924479A (zh) * 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
CA2138644A1 (en) * 1992-07-08 1994-01-20 Bert M. Glaser Method of treating ophthalmic disorders using tgf-.beta.
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
AU756515B2 (en) * 1998-03-13 2003-01-16 Johns Hopkins University School Of Medicine, The The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Also Published As

Publication number Publication date
DK1131073T3 (da) 2004-02-02
JP2002530342A (ja) 2002-09-17
ES2211197T3 (es) 2004-07-01
BR9915569A (pt) 2001-08-14
HK1040182A1 (en) 2002-05-31
EP1131073B1 (en) 2003-10-22
KR20010078398A (ko) 2001-08-20
CN1172673C (zh) 2004-10-27
NO328085B1 (no) 2009-11-30
DE69912304D1 (de) 2003-11-27
CN1328462A (zh) 2001-12-26
ID29970A (id) 2001-10-25
AU1506600A (en) 2000-06-13
IL142757A (en) 2007-07-04
DE69912304T2 (de) 2004-07-22
IL142757A0 (en) 2002-03-10
PT1131073E (pt) 2004-03-31
NO20012490D0 (no) 2001-05-21
KR100698449B1 (ko) 2007-03-23
AU761092B2 (en) 2003-05-29
JP2011088938A (ja) 2011-05-06
NZ511559A (en) 2004-01-30
CA2348890C (en) 2009-05-12
ATE252387T1 (de) 2003-11-15
EP1131073A1 (en) 2001-09-12
NO20012490L (no) 2001-06-25
CA2348890A1 (en) 2000-06-02
WO2000030651A1 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
JP2011088938A (ja) 眼血管新生疾患の処置のためのスタウロスポリン誘導体の使用
Tokushige et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys
AU2016276170B2 (en) Compositions and methods for treating pterygium
CA2454976C (en) Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
KR101286883B1 (ko) 각결막 장애의 예방 또는 치료제
WO2010113753A1 (ja) ＪＮＫ（ｃ－Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを用いた網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、ならびに、その使用
CN110662549A (zh) 用于治疗眼病的组合物和方法
US10357453B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
US6214819B1 (en) Method for treating ocular neovascular diseases
US20030007971A1 (en) Remedies for ophthalmic diseases
KR20150058159A (ko) 바클로펜 및 아캄프로세이트 기반 황반 변성 장애의 치료
US20030153551A1 (en) Method for treating ocular neovascular diseases
MXPA01005152A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
WO2010056710A1 (en) Compositions and methods for treating eye diseases
US8273708B2 (en) Methods of treatment of ocular surface pathologies
JP2004331502A (ja) 視神経細胞保護剤
JP4456269B2 (ja) 視神経乳頭循環改善剤
CA2398900A1 (en) Therapeutic agents for opthalmopathy
JP4393863B2 (ja) 視神経細胞保護剤
WO2000067740A9 (en) Aminoguanidine for treating glaucomatous optic neuropathy
JPH10120569A (ja) 眼疾患予防または治療剤
US20140213605A1 (en) Methods for treating eye disorders using opioid receptor antagonists